Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Clinical Impact of p27Kip1 and CaSR Expression on Primary Hyperparathyroidism.

Sengul Aycicek G, Aydogan BI, Sahin M, Cansız Ersoz C, Sak SD, Baskal N.

Endocr Pathol. 2018 Sep;29(3):250-258. doi: 10.1007/s12022-018-9524-9.

PMID:
29589297
2.

Risk Factors and Frequency of Ingrown Nails in Adult Diabetic Patients.

Vural S, Bostanci S, Koçyigit P, Çaliskan D, Baskal N, Aydin N.

J Foot Ankle Surg. 2018 Mar - Apr;57(2):289-295. doi: 10.1053/j.jfas.2017.10.006. Epub 2018 Jan 10.

PMID:
29329712
3.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

4.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

5.

Annexin V expression and anti-annexin V antibodies in type 1 diabetes.

Bakar F, Unlütürk U, Başkal N, Nebioğlu S.

J Clin Endocrinol Metab. 2014 Mar;99(3):932-7. doi: 10.1210/jc.2013-2592. Epub 2014 Jan 1.

PMID:
24423325
6.

Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism.

Ağbaht K, Erdogan MF, Emral R, Baskal N, Güllü S.

Endocrine. 2014 Feb;45(1):106-13. doi: 10.1007/s12020-013-9951-9. Epub 2013 Apr 10.

PMID:
23572405
7.

Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults.

Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J; TURDEP-II Study Group.

Eur J Epidemiol. 2013 Feb;28(2):169-80. doi: 10.1007/s10654-013-9771-5. Epub 2013 Feb 14.

8.

Improvement in remission rates of the first operation in acromegalic patients.

Demir O, Gedik V, Corapcioglu D, Emral R, Unlu MA, Erdogan MF, Gullu S, Uysal AR, Baskal N.

Turk Neurosurg. 2012;22(5):645-50. doi: 10.5137/1019-5149.JTN.6045-12.0.

9.

Ultrasound elastography is not superior to grayscale ultrasound in predicting malignancy in thyroid nodules.

Unlütürk U, Erdoğan MF, Demir O, Güllü S, Başkal N.

Thyroid. 2012 Oct;22(10):1031-8. doi: 10.1089/thy.2011.0502. Epub 2012 Aug 9.

PMID:
22876757
10.

The role of ultrasound elastography in preoperative localization of parathyroid lesions: a new assisting method to preoperative parathyroid ultrasonography.

Ünlütürk U, Erdoğan MF, Demir O, Culha C, Güllü S, Başkal N.

Clin Endocrinol (Oxf). 2012 Apr;76(4):492-8. doi: 10.1111/j.1365-2265.2011.04241.x.

PMID:
21955171
11.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
12.

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.

13.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
14.

Hypokalemic paralysis is not just a hypokalemic paralysis.

Cesur M, Ilgin SD, Baskal N, Gullu S.

Eur J Emerg Med. 2008 Jun;15(3):150-3. doi: 10.1097/MEJ.0b013e3282bf6ee3.

PMID:
18460955
15.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327
16.

Effect of simvastatin use on bone mineral density in women with type 2 diabetes.

Uysal AR, Delibasi T, Erdogan MF, Kamel N, Baskal N, Tonyukuk V, Corapcioglu D, Güllü S, Erdogan G.

Endocr Pract. 2007 Mar-Apr;13(2):114-6.

PMID:
17490923
17.

Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism.

Erdoğan MF, Anil C, Cesur M, Başkal N, Erdoğan G.

Thyroid. 2007 Mar;17(3):223-8.

PMID:
17381355
18.

Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N.

Eat Weight Disord. 2006 Dec;11(4):e127-32.

PMID:
17272944
19.

Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.

Gürsoy A, Erdoğan MF, Cin MO, Cesur M, Başkal N.

Endocr Pract. 2005 Sep-Oct;11(5):308-12.

PMID:
16191490
20.

A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis.

Erdogan MF, Güleç S, Tutar E, Başkal N, Erdogan G.

Thyroid. 2003 Feb;13(2):205-9.

PMID:
12699596

Supplemental Content

Loading ...
Support Center